Compounded Semaglutide in South Africa: Legal Checks for Consumers

Key takeaways

• Compounded semaglutide is not automatically lawful or unlawful in South Africa. Compounding is a narrow exception to medicine registration for a preparation made for an individual patient by an authorised professional, within section 14(4) of the Medicines and Related Substances Act and the General Regulations. It is not a way to manufacture, advertise or distribute an unregistered product to the general market.
• A consumer should distinguish three separate questions: whether the exact marketed product is registered by the South African Health Products Regulatory Authority (SAHPRA), whether a patient-specific compounded preparation meets the legal conditions, and whether the prescriber, pharmacy and supply chain are properly registered or licensed. A claim that an ingredient is used in a registered medicine does not mean the compounded preparation itself was reviewed or registered by SAHPRA.
• This guide reflects official material checked on 20 July 2026. Registration entries, recalls and enforcement notices can change, so verify the exact product and supplier against the live official registers before relying on a label or advertisement.

1. Start by identifying what was actually offered

Do not assess the transaction from the words “semaglutide”, “GLP-1” or “compounded” alone. Ask the seller or dispensing pharmacy for the facts that identify the product and legal route:

• the exact product or preparation name;
• the active ingredient as stated on the label;
• the dosage form and strength;
• whether it is claimed to be a SAHPRA-registered product or an individually compounded preparation;
• the SAHPRA registration number, if registration is claimed;
• the patient's name and dispensing reference;
• the prescriber's full name and professional registration details;
• the dispensing pharmacy's name, physical address and registration details;
• the person who compounded or dispensed it; and
• the batch, lot, compounding, dispensing and expiry or use-by information supplied.

Take clear photographs of every side of the container and outer packaging before separating or discarding them. Preserve the prescription, invoice, delivery record and messages that describe what was promised. Do not post a patient's unredacted label, prescription or identity details publicly.

The legal analysis changes if the seller claims the item is a registered branded medicine, a generic, an imported product, a section 21 authorisation, or a compounded medicine. Ask for the claimed basis in writing rather than trying to infer it from a social-media post.

2. Registered medicine and compounded preparation are not the same

SAHPRA assesses a medicine submitted for registration and maintains current medicine information through its online directory and product-information repository. Registration attaches to the identified product, applicant, formulation, strength, dosage form and authorised particulars. It does not attach to an ingredient in the abstract or automatically extend to another seller's vial, pen or mixture.

A compounded preparation follows a different legal route. SAHPRA's semaglutide FAQ explains that compounded medicines are not reviewed by the regulator for registration and that SAHPRA does not verify each compounded preparation's safety, quality or efficacy. A seller should therefore not describe a compounded preparation as “SAHPRA approved” merely because semaglutide appears in a registered medicine.

The separate Lexuno medicine-approval article owns the broader registration question. For this product-specific enquiry, record exactly which status the supplier claims and check it against SAHPRA's live Medicines Online Directory. A missing search result is a reason to ask SAHPRA or a registered pharmacist for verification; it is not, by itself, a final legal finding about every possible authorisation route.

Product registrations and authorised indications also change. Do not rely on an older article, screenshot or statement about how many semaglutide products are registered. Check the current directory and the current professional and patient information for the exact product.

3. The compounding exception is patient-specific and limited

Section 14 generally prohibits the sale of a medicine that is subject to registration but is not registered. Section 14(4) creates a limited exclusion for qualifying compounded medicines. The 2017 General Regulations add operational conditions.

For a consumer transaction, the following questions matter:

1. Was it prepared for an identified patient? The regulatory definition connects compounding by a pharmacist to an individual patient and compounding by another authorised dispenser to a prescription for a patient.
2. Was there a proper prescription and diagnosis? A person licensed to compound and dispense under section 22C(1)(a) must act after a proper diagnosis and under a compliant prescription for a particular patient. The professional's exact authority and scope still need verification.
3. Who compounded it? The Act and regulations identify pharmacists and appropriately licensed dispensers, acting within their professional scope. A marketing company, gym, wellness seller or anonymous online account cannot acquire compounding authority merely by arranging delivery.
4. How much was prepared? Regulation 3 limits the compounded quantity to what the patient is intended to use for no more than 30 consecutive days from the compounding date.
5. Was it advertised or displayed for sale? A medicine compounded under section 14(4) may not be advertised or displayed for sale.
6. Does the preparation use a permitted active component? Section 14(4) and SAHPRA's guidance require the active components to be included in another medicine registered under the Act, subject to the remaining statutory exclusions.
7. Was good practice followed? Regulation 3 bars compounding unless it is performed according to good practice determined by the regulator.

These conditions operate together. A prescription does not cure unrelated unlawful manufacture, importation, advertising or distribution. Equally, a consumer should not accuse a specific pharmacy of illegality solely because the medicine was compounded; obtain the prescription, label, register entries and supply-chain facts first.

4. Semaglutide salts and ingredient claims require exact wording

SAHPRA's semaglutide guidance specifically warns about products made with semaglutide sodium, semaglutide acetate or another form that differs from the active ingredient in the registered product. The regulator states that those salt forms are not permissible under section 14(4) and have not been evaluated by SAHPRA for safety or effectiveness.

Ask the pharmacy to state the active ingredient exactly as it appears in the source documentation and on the dispensing record. Do not accept “same as”, “generic Ozempic”, “research grade”, “peptide blend” or a similar marketing phrase as proof of identity or lawful status.

Do not attempt to identify an injectable product from colour, viscosity, packaging or the seller's before-and-after photographs. Laboratory identity, potency, purity and sterility cannot be established by visual inspection. SAHPRA's public peptide guidance warns about unregistered powders and informal supply channels and directs consumers towards registered products, licensed pharmacies and registered health professionals.

This article does not advise whether any person should start, continue, stop or change a medicine. Questions about treatment, side effects or a missed dose belong with a registered medical practitioner or pharmacist who can assess the person and the exact product.

5. Check the patient label before accepting supply

The General Regulations specify core particulars for a medicine supplied for a particular patient under the relevant exemptions. A compounded semaglutide label should be checked for:

• the approved or proprietary name, or the name of each active ingredient or constituent medicine;
• the name of the patient for whom it was supplied;
• directions for use;
• the authorised seller's name and business address;
• the dispensing date;
• a reference number;
• the compounding date; and
• the required instruction that it be used within 30 days.

The presence of these particulars does not prove every legal or quality requirement was met. Their absence, a label for a different patient, unexplained relabelling, an anonymous courier pack or a mismatch between the invoice and container is a reason to pause and obtain written clarification.

Do not alter the label or transfer the contents to an unmarked container. If the product is subject to a recall, regulator enquiry or complaint, the original container and packaging may connect it to the supplier, dispensing record and affected batch.

6. Verify the pharmacy, prescriber and supply chain

Use the South African Pharmacy Council (SAPC) public register to search for the pharmacy and the relevant pharmacy professional. The register supports searches for pharmacies and registered persons. Match the result to the physical address and details on the label; a similar trading name is not enough.

For a medical practitioner, use the Health Professions Council of South Africa register and record the practitioner's full name and registration number. A telehealth interaction does not remove the need for a properly identified, registered prescriber acting within professional rules.

Ask the dispensing pharmacy:

• whether it prepared the item itself or received it from another facility;
• where the active ingredient and other components came from;
• whether it holds the relevant pharmacy registration and medicine licences;
• which responsible pharmacist can answer a product-quality question;
• whether any recall, rapid alert or regulator instruction affects the preparation; and
• how an adverse event or quality defect should be reported.

SAHPRA and SAPC announced joint enforcement action in May 2026 after an inspection found GLP-1 and GIP products being produced and supplied outside the patient-specific compounding framework. The regulators reported seizure and recall action as well as concerns about imported active ingredients, analytical testing and sterile conditions. Those official findings show why the full chain matters, but they do not prove that a different supplier committed the same contraventions.

7. Advertising can reveal a mismatch with lawful compounding

Regulation 3 says a section 14(4) compounded medicine may not be advertised or displayed for sale. Preserve any public page, message or brochure that offers standardised compounded semaglutide products, recurring packages or broad delivery before a named patient's prescription exists.

Record:

• the complete page address and date;
• the account name and contact details;
• the exact product description and photographs;
• claims about registration, approval, generic status, ingredients or expected results;
• price, subscription and delivery terms;
• whether a consultation or prescription occurred before payment;
• who received the money; and
• who ultimately prescribed, compounded, dispensed and delivered the item.

Do not edit screenshots in a way that removes context. Save the original confirmation email, invoice or downloadable document as well. If a claim later disappears, the full record is more useful than a cropped image of a single sentence.

Avoid repeating health or weight-loss claims in a public accusation. Send the evidence to the regulator or professional body that can test it against the Act, registration particulars and professional records.

8. Red flags that require verification

No single warning sign decides the matter. A combination of the following should trigger a written query and an official register check:

• the preparation is sold without identifying the patient or prescriber;
• a standard product menu is publicly advertised as “compounded”;
• the seller calls it “SAHPRA approved” but will not provide an exact registration number;
• the label omits the patient, business address, dates, directions or reference;
• the product name, strength or active ingredient differs across the prescription, label and invoice;
• the description refers to semaglutide sodium, semaglutide acetate or a “research” peptide;
• payment goes to an unrelated person or entity that is not explained;
• a social-media account, gym or marketing agent is the only identifiable supplier;
• the seller refuses to identify the physical pharmacy or responsible pharmacist;
• cold-chain, tamper or contamination concerns are dismissed without investigation;
• the container appears reused, unsealed or relabelled; or
• SAHPRA has published a recall, warning or rapid alert affecting the product or source.

Do not use a suspicious product to create evidence. If there is a health concern, seek appropriate professional medical assistance promptly and follow the regulator's reporting route. Preserve the product safely and ask SAHPRA or the dispensing pharmacy how it should be handled; do not send an injectable through ordinary post without instructions.

9. Build one evidence file

An effective regulatory or consumer complaint should allow the recipient to identify the people, product, transaction and problem without reconstructing them from chat fragments.

Create an indexed file containing:

The consumer complaint checklist can organise the transaction record. Keep clinical documents private and disclose them only where relevant to the healthcare professional, regulator, professional body, insurer or legal adviser handling the matter.

10. Choose the complaint route by issue

Different bodies answer different questions. Sending the same undifferentiated complaint everywhere can slow fact-finding.

The Consumer Protection Act includes rights concerning fair marketing, safe and good-quality goods, an implied warranty of quality and possible product-liability claims. It does not make every disappointing result a defect, prove who caused an injury or guarantee a refund in every medicine dispute. The remedy depends on the representation, product, defect, timing, chain of supply, use, loss and available evidence.

Start a consumer claim with a dated written notice to the supplier that identifies the transaction, problem, supporting record and remedy requested. If it is unresolved, the CGSO assesses whether the matter falls within its jurisdiction and can refer it through its complaint process. The consumer-protection glossary and consumer-rights resources provide the wider route context.

11. Recalls, evidence and urgent safety are separate

A product recall is a regulator or supplier control step; it is not automatically proof of individual injury or an admission of civil liability. Follow the notice's product identifiers and return instructions. Keep a copy of the notice and record whether the product, batch and source match.

Preserving evidence must never take priority over urgent care. A person experiencing a suspected serious reaction should seek appropriate medical assistance and identify the exact product if possible. Ask the healthcare provider to record the product name, label details and supply source accurately.

For a later legal assessment, separate:

• what the seller represented;
• what product was actually supplied;
• which legal route was claimed;
• what the official registers showed on the relevant date;
• what defect, contamination, misdescription or contravention is alleged;
• what clinical event or financial loss occurred; and
• which expert or official evidence connects those facts.

The lawyer directory may assist where injury, a contested refund, misleading marketing, multiple suppliers or regulatory action creates a fact-specific dispute. Lexuno is not the regulator, a pharmacy or a medical provider and does not verify a product's clinical suitability.

FAQs

Related Lexuno paths